Valuation: Dermapharm Holding SE

Market Cap 1.91B 2.14B 1.74B 1.59B 2.99B 202B 3.08B 20.96B 8.38B 107B 8.03B 7.86B 338B P/E 2026 *
14.8x
P/E 2027 * 13.1x
Enterprise Value 2.72B 3.05B 2.49B 2.27B 4.27B 288B 4.38B 29.88B 11.95B 153B 11.45B 11.21B 482B EV / Sales 2026 *
2.25x
EV / Sales 2027 * 2.07x
Free-Float
10.7%
Yield 2026 *
2.62%
Yield 2027 * 2.93%
1 day-0.84%
1 week+0.79%
Current month-0.13%
1 month+2.67%
3 months-7.00%
6 months-16.30%
Current year-2.16%
1 week 38.25
Extreme 38.25
39.35
1 month 37.35
Extreme 37.35
39.35
Current year 34.3
Extreme 34.3
51.9
1 year 32.95
Extreme 32.95
51.9
3 years 30.15
Extreme 30.15
51.9
5 years 30.15
Extreme 30.15
91.95
10 years 21.58
Extreme 21.575
91.95
Manager TitleAgeSince
Chief Executive Officer 64 01/08/2017
Director of Finance/CFO - 01/11/2022
Investor Relations Contact - 01/12/2018
Director TitleAgeSince
Chairman 70 01/08/2017
Director/Board Member 66 01/08/2017
Director/Board Member 78 01/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
5/14/26 A Buy

Chairman

380,000 0.7670%
1/7/26 A Buy 150 0.0003%
1/7/26 A Buy 150 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-1.03%+0.79%+16.67%+1.85% 2.16B
-3.76%-0.65%+47.41%+129.29% 1,263B
-1.45%-1.05%+46.41%+79.51% 665B
-2.24%-0.88%+32.97%+104.14% 521B
-1.06%-1.78%+48.37%+65.10% 387B
-2.27%+0.42%+74.12%+40.83% 371B
-0.10%+3.79%+32.16%+60.93% 310B
+0.13%+10.01%+12.08%+36.73% 293B
-3.80%-0.10%+43.90%+68.71% 259B
-3.96%+1.18%+36.70%+106.52% 216B
Average -1.83%+5.22%+39.08%+69.36% 428.76B
Weighted average by Cap. -2.23%+5.96%+43.61%+88.93%

Financials

2026 *2027 *
Net sales 1.21B 1.36B 1.11B 1.01B 1.9B 128B 1.95B 13.28B 5.31B 67.88B 5.09B 4.98B 214B 1.25B 1.41B 1.15B 1.04B 1.97B 133B 2.02B 13.78B 5.51B 70.45B 5.28B 5.17B 222B
Net income 137M 154M 126M 114M 216M 14.56B 221M 1.51B 603M 7.71B 578M 566M 24.32B 155M 174M 142M 129M 244M 16.47B 250M 1.71B 683M 8.72B 654M 640M 27.53B
Net Debt 812M 911M 742M 676M 1.27B 86.08B 1.31B 8.92B 3.57B 45.59B 3.42B 3.35B 144B 687M 771M 628M 572M 1.08B 72.84B 1.11B 7.55B 3.02B 38.58B 2.89B 2.83B 122B
Projected Income Statement - Annual - Dermapharm Holding SE
Logo Dermapharm Holding SE
Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Employees
3,619
Date Price Change Volume
05/11/26 €38.50 -1.03% 13,229
04/11/26 €38.90 +1.17% 8,350
03/11/26 €38.45 -1.66% 13,592
02/11/26 €39.10 +1.43% 8,213
30/10/26 €38.55 0.00% 5,424
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Dermapharm Holding SE
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
38.90EUR
Average target price
51.00EUR
Spread / Average Target
+31.11%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Dermapharm Holding SE